A
Antiva Biosciences
A biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection
About Antiva Biosciences
Antiva Bio is a healthcare startup that focuses on the development of innovative topical treatments for pre-cancerous cervical lesions and the Human Papillomavirus (HPV) infections that cause these lesions. The company's primary market is women who are diagnosed with HPV infections and pre-cancerous cervical lesions.
Currently, there is no treatment for HPV infection, and women are often left in a state of uncertainty, waiting to see if their infection clears up on its own or progresses to a more severe disease. Antiva Bio aims to change this by developing a first-of-its-kind therapy that women can use to treat themselves at home as soon as their infection is diagnosed.
This therapy also offers a non-surgical alternative for women whose disease has progressed further. This means that Antiva Bio's business model is centered around providing a simple, convenient, and non-invasive solution to a global health issue.
The company generates revenue by developing and selling these novel therapies. Their experienced team is committed to improving health outcomes and access to care worldwide, aligning with the World Health Organization’s global Cervical Cancer Elimination Initiative.
In summary, Antiva Bio is a pioneering healthcare startup that is developing innovative, home-based, non-surgical treatments for HPV infections and pre-cancerous cervical lesions, with a mission to improve women's health outcomes globally.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES EOther financing | Apr 2023 | $53M | $212M | Canaan · Lumira Ventures · BioImpact Capital · GV | ↗ |
| SERIES DOther financing | Nov 2021 | $31M | $124M | Canaan · Brace Pharma · Gaingels · HBM Healthcare Investments | — |
Growth signals
Latest recorded traffic for Antiva Biosciences is 2.7K monthly website visits, up 50% over the last three months. Antiva Biosciences's team declined 30.8% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Antiva Biosciences in the Redwood City ecosystem
The Antiva Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Canaan
Sofinnova Investments- WHWende Hutton
Series B and later15 investors entered at this stage
Brace Pharma
Osage University Partners
Alexandria Venture Investments
Hillhouse Capital- SCSirona Capital
Lumira Ventures
Adjuvant Capital
Gaingels
HBM Healthcare Investments
Dong-A ST
Mana Ventures
Avestria Ventures
MPM BioImpact
BioImpact Capital
GV
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Antiva Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Antiva Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










